<i>circ<scp>MAN</scp>1A2</i> could serve as a novel serum biomarker for malignant tumors

Fan, Chongxi; Wang, Jin‐Peng; Tang, Yue; Jin, Zhao; He, Shuyi; Xiong, Fang; Guo, Can; Xiang, Bo; Zhou, Ming; Li, Xiaoling; Li, Yong; Li, Gui‐Yuan; Xiong, Wei; Zeng, Zhaoyang

doi:10.1111/cas.14034

Cited by 100 publications

(68 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies have suggested that patients with the BRAF V600E mutation should be overtreated to some extent [47], because BRAF mutations are an independent risk factor for lymph node metastasis and are closely related to tumor size and invasiveness [48][49][50][51][52][53][54][55][56][57]. Both the clinical studies and the basic medical studies performed here suggest that the presence of the BRAF mutation may lead to a decrease in the efficacy of iodine-131 treatment.…”

Section: Discussionmentioning

confidence: 73%

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer

Wang

et al. 2020

J. Cancer

Self Cite

View full text Add to dashboard Cite

Objective: To investigate the correlation between the BRAF V600E gene mutation and clinicopathological features and thyroid function after iodine-131 treatment in patients with papillary thyroid cancer (PTC). Methods: A total of 128 PTC patients who underwent iodine-131 treatment after a total thyroidectomy from February 2015 to November 2016 at Hunan Cancer Hospital, China, were recruited. There were 25 males and 103 females. The age range was 11 to 73 years old. The BRAF V600E mutation in tumor tissues was detected by amplification-restriction mutation system polymerase chain reaction (ARMS-PCR), and the serum levels of Tg, TSH, Tg-Ab, and Tpo-Ab were measured by chemiluminescence after iodine-131 treatment. The BRAF V600E mutation was shown to be associated with clinicopathological characteristics and thyroid function indicators after iodine-131 treatment. Results: BRAF V600E mutation was detected in 75 of the 128 patients (58.6%) and was observed more frequently in cases with elevated Tg levels (Tg>1.00) at 3, 6, 12, and 18 months after treatment compared with patients without any BRAF mutations (P<0.05). Patients with BRAF V600E mutation had significant lower level of Tg-Ab at 3 and 12 months after treatment with iodine-131 than patients without BRAF V600E mutation (P<0.05). Among the 75 BRAF V600E patients, no significant association was found between the levels of TSH and Tpo-Ab after iodine-131 treatment (P>0.05). The BRAF V600E mutation was closely associated with the high-risk and age of the patient (≥45 years old) (P<0.05), but there was no significant correlation with gender, clinical stage, and distant metastasis. Conclusion:The BRAF V600E mutation is closely related to serum Tg elevation after treatment with iodine-131 in papillary thyroid cancer. These findings suggest that this BRAF mutation may be a predictor of the efficacy of iodine-131 treatment for papillary thyroid cancer.

show abstract

Section: Discussionmentioning

confidence: 73%

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer

Wang

et al. 2020

J. Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition to the interaction between PVT1 and MYC, the newly discovered molecule CircPVT1 is also associated with MYC [145][146][147][148][149]. CircPVT1 is highly expressed in cancer and can mediate the expression of c-Myc [22,150].…”

Section: Perspectivesmentioning

confidence: 99%

Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis

Jin

Wang

Zhang

et al. 2019

Cell. Mol. Life Sci.

Self Cite

112

View full text Add to dashboard Cite

Numerous studies have shown that non-coding RNAs play crucial roles in the development and progression of various tumor cells. Plasmacytoma variant translocation 1 (PVT1) mainly encodes a long non-coding RNA (lncRNA) and is located on chromosome 8q24.21, which constitutes a fragile site for genetic aberrations. PVT1 is well-known for its interaction with its neighbor MYC, which is a qualified oncogene that plays a vital role in tumorigenesis. In the past several decades, increasing attention has been paid to the interaction mechanism between PVT1 and MYC, which will benefit the clinical treatment and prognosis of patients. In this review, we summarize the coamplification of PVT1 and MYC in cancer, the positive feedback mechanism, and the latest promoter competition mechanism of PVT1 and MYC, as well as how PVT1 participates in the downstream signaling pathway of c-Myc by regulating key molecules. We also briefly describe the treatment prospects and research directions of PVT1 and MYC.

show abstract

“…Compared with other detection methods, liquid biopsy has become the preferredchoice for disease screening because of its non-invasiveness, low cost, easeof use, and high stability. Some biomarkers for HNCs, including proteins, miRNAs, and EBV DNA, have been identified using liquid biopsies [39,40]. However, each of these markers has its own disadvantages, including low positive rates, high false positive rate, need for experienced operators, and instrumental limitations.…”

Section: Discussionmentioning

confidence: 99%

Upregulation of long non-coding RNA LOC284454 may serve as a new serum biomarker for head and neck cancers

Fan¹,

Wang²,

Tang³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Purpose: Identification of effective diagnostic and prognostic biomarkers of cancer is necessary for improving precision medicine. Long non-coding RNAs(lncRNAs) play an important regulatory role in tumorinitiation and progression. The lncRNA LOC284454 is distinctly expressed in various head and neck cancers(HNCs), as demonstrated by our previous bioinformatics analysis. However, the expression levels and functions of LOC284454 in cancer are still unclear.Methods: We investigated the dysregulation of lncRNAs in HNCs using the GEO database and found that LOC284454 was highly expressed in HNCs. Serum samples from 212 patients with HNCs and 121 normal controls were included in this biomarker study. We measured the expression of LOC284454 in the sera of HNC patients and normal controls using RT-qPCR. Receiver operating characteristics (ROC) analysis is an important statistical method that is widely used in clinical diagnosis and population screening. ROC was used to analyze the clinical value of LOC284454 in the early diagnosis of HNCs.Results: LOC284454 was significantly upregulated in the sera of patients with nasopharyngeal carcinoma, oral cancer, and thyroid cancer. LOC284454 upregulation had good clinical diagnostic value in these cancers, as evaluated by area under the ROC curve values of 0.931, 0.698, and 0.834,respectively.Conclusions: LOC284454 may be a valuable serum biomarker forHNCsfacilitating the early diagnosis of malignant cancers.Further studies are needed to elucidate the mechanisms underlying the involvement of LOC284454 in HNCs.This study provides the first evidence that LOC284454 may be a serum biomarker for HNCs.

show abstract

circMAN1A2 could serve as a novel serum biomarker for malignant tumors

Cited by 100 publications

References 84 publications

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer

Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis

Upregulation of long non-coding RNA LOC284454 may serve as a new serum biomarker for head and neck cancers

Contact Info

Product

Resources

About